Clinical Report: Epigenetic Markers May Predict Glaucoma Progression
Overview
A recent study indicates that epigenetic age acceleration is significantly associated with the rate of glaucoma progression in primary open-angle glaucoma (POAG) patients. Fast progressors exhibited greater biological aging, as measured by DNA methylation patterns, compared to slow progressors.
Background
Understanding the mechanisms underlying glaucoma progression is crucial for improving patient outcomes. Traditional risk factors, such as intraocular pressure (IOP), do not fully account for disease variability, highlighting the need for additional predictive markers. This study explores the potential of epigenetic markers to enhance risk stratification and management in glaucoma.
Data Highlights
| Measurement | Fast Progressors | Slow Progressors | P-value |
|---|---|---|---|
| Horvath AgeAccel (mean difference) | 2.93 years | Reference | <.001 |
| Hannum AgeAccel (mean difference) | 1.24 years | Reference | .045 |
Key Findings
- Fast progressors had significantly greater epigenetic age acceleration than slow progressors.
- Each additional year of Horvath AgeAccel increased the odds of fast progression by 15% (P<.001).
- In patients with no history of elevated IOP, the mean age acceleration was almost five years for the Horvath clock.
- Biological aging may contribute to optic nerve susceptibility beyond IOP-related damage.
- Predictive models incorporating epigenetic age may identify fast progressors, warranting further prospective validation.
Clinical Implications
Incorporating epigenetic aging metrics into clinical practice may enhance the ability to predict glaucoma progression. This could lead to more tailored management strategies for patients, particularly those with lower IOP but rapid disease progression.
Conclusion
The findings suggest that epigenetic markers could serve as valuable tools in predicting glaucoma progression, potentially guiding therapeutic interventions. Further research is needed to validate these results and explore their clinical applications.
References
- Medeiros FA, Jammal A, American Glaucoma Society, 2025 -- Epigenetic Markers May Predict Glaucoma Progression
- Le BM, Pasquale LR, Ophthalmology Management, 2023 -- The Importance of Genetic Biomarkers for Glaucoma
- Sekimitsu S, Wiggs JL, Zebardast N, Ophthalmology Management, 2023 -- Genetic Predisposition to Glaucoma
- Ophthalmology Management, 2017 -- Monitoring Glaucoma Progression with OCT
- Pazos M, Traverso CE, Viswanathan A, et al., 2026 -- Advancing glaucoma care: What's new in the 6th edition of the European Glaucoma Society guidelines
- optometric management — Progression Is the Name of the Game in Glaucoma
- EVIDENCE-BASED CLINICAL PRACTICE GUIDELINECare of the Patient
- Advancing glaucoma care: What's new in the 6th edition of the European Glaucoma Society guidelines - Marta Pazos, Carlo E Traverso, Ananth Viswanathan, Augusto Azuara-Blanco, Luis Abegão Pinto, Ingeborg Stalmans, 2026
- Accelerated Epigenetic Aging Is Associated with Faster Glaucoma Progression: A DNA Methylation Study - PubMed
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.